Project Grant R01AI183970
Award Date
8/20/24
Completion Date
7/31/29
Dollars Obligated
$1.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Hampshire, USA
Similar Awards
This $3,454,926 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to define the optimal pathway from antibody precursors to broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein apex epitope. The research aims to refine the understanding of common apex bNAb precursors found in uninfected individuals and identify SOSIP-TM antigens that can...
This federal Project Grant award in the amount of $1,501,625.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to develop broadly neutralizing nanobodies as a novel therapeutic approach for advancing HIV/AIDS treatment. The key objectives are to: 1) Identify versatile nanobodies capable of recognizing diverse regions of the HIV envelope protein through advanced...
This federal Project Grant award, valued at $742,463.00 and made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to exploit glycan holes and sequence diversity of naturally occurring HIV envelope proteins for the design of vaccine immunogens capable of inducing broad neutralization. The research aims to leverage innovative computational and in vitro approaches to select HIV envelope...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $107,948 to the University of Southern California (USC) to develop an approach to engineer B cells to secrete broadly neutralizing antibodies (bNAbs) that can control HIV in people living with HIV (PLWH). The key objectives of this 4.5-year project are to: 1) design synthetic protein signaling molecules that can...
This Project Grant award, with a total funding amount of $667,848, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research to investigate the molecular and phenotypic features of pre-existing HIV gp120-specific B cells, and how these B cell populations respond to HIV vaccination in high-risk individuals, including those using pre-exposure prophylaxis (PrEP). The...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $108,256 to fund research aimed at eliciting broadly neutralizing antibodies (bNAbs) against HIV-1 through a two-pronged approach. The first aim involves rigorously dissecting the evolution of a bNAb precursor-like lineage using an immunoglobulin knockin mouse model. The second aim will study antibody-virus coevolution...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an effective HIV vaccine regimen that elicits both broadly neutralizing antibodies and high-quality T-cell responses. The $7,105,240 award supports a 5-year research program with the University of California, Davis as the prime recipient. The program includes three main projects: Project 1 will examine...
This $737,761.00 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) aims to enhance HIV prevention with a vaccine approach that promotes durable immunity. The key products and services to be delivered include: Detailed immune analyses to uncover mechanisms of effective T follicular helper (Tfh) cell-mediated humoral immunity against HIV, using both DNA and mRNA vaccine platforms in rhesus macaques. The...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to define the role of antibody glycosylation in regulating natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) during HIV infection. The $142,908 award will support research activities to determine how specific antibody glycosylation profiles modulate CD16 interactions and ADCC...
This federal Project Grant award, totaling $243,713.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, with a performance period from January 27, 2025 to December 31, 2026, aims to determine the mechanisms by which HIV-infected macrophages resist antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells. Specifically, the research will characterize...